Biofarma Says Owners Hire Goldman Sachs for Sale of Stake

Biofarma Pharmaceutical Industry Co.’s owners hired Goldman Sachs Group Inc. to start the process of selling a stake in the Turkish drugmaker, Chief Executive Officer Serdar Sozeri said.

Goldman sent out so-called teasers, or invitation letters, to potential bidders for stock in the Istanbul-based company, which is owned equally by New York-based private-equity firm Rohatyn Group and another buyout investor group that Sozeri, speaking in a phone interview, identified as Spokane while declining to specify other details. He also declined to comment on the size of any holding that might be offered.

Citi Venture Capital International, a unit of Citigroup Inc. (C) that was sold to Rohatyn Group last year, and Partners in Life Sciences bought Biofarma, a generic producer of heart, respiratory and urinary-tract treatments, from its Turkish owners in 2006. A stake was sold to Greek private-equity firm Global Finance in 2007.

An attempt to sell the drugmaker in 2011 failed over price, with a person familiar with the situation at the time estimating the drugmaker was valued at $600 million to $700 million. A spokesman for Rohatyn didn’t immediately return a call seeking comment.

Bayer AG, GlaxoSmithKline Plc (GSK), Novartis AG (NOVN), AstraZeneca Plc (AZN) and Amgen Inc. are among more than 30 international drugmakers operating in Turkey, a medicines market that expanded 6.5 percent to 15.2 billion liras ($7.2 billion) in 2013, according to the website of the Istanbul-based Pharmaceutical Manufacturers’ Association of Turkey. Biofarma’s revenue in 2010 totaled 160 million liras, according to Istanbul Chamber of Industry figures.

To contact the reporter on this story: Ercan Ersoy in Istanbul at eersoy@bloomberg.net

To contact the editors responsible for this story: Benedikt Kammel at bkammel@bloomberg.net Tom Lavell, David Risser

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.